Glucotrack, Inc. 8-K

What Happened
Glucotrack, Inc. announced that on July 14, 2026 it closed a merger with Lokahi Therapeutics, Inc., making Lokahi a direct wholly owned subsidiary. As structured, Lokahi’s former common stockholders receive Merger Consideration consisting of Glucotrack common stock and Series A convertible preferred stock such that, on a fully‑diluted, as‑converted basis, those holders collectively own 90.0% of Glucotrack equity immediately after the merger (with existing Glucotrack stockholders protected by a 10.0% minimum floor). The filing also discloses simultaneous financing transactions: a Bridge Financing raising approximately $4.45 million via senior secured convertible notes and warrants, and an equity line (ELOC) with White Lion Capital giving Glucotrack the right to raise up to $50 million over three years. Effective at closing, Erik Emerson was appointed CEO of Glucotrack and Paul V. Goode stepped down.

Key Details

• Closing date: July 14, 2026; Lokahi merged into Glucotrack Merger Sub and became a wholly owned subsidiary.
• Post‑merger ownership: Lokahi holders to hold 90.0% of fully‑diluted equity; existing Glucotrack holders to hold at least 10.0% (Acquiror Stockholder Floor).
• Series A preferred: 1,000,000 shares designated; stated value $40.30; automatic conversion into common at 1:100 shares per preferred upon stockholder approval and Nasdaq listing/continuing‑listing conditions.
• Bridge Financing: ~ $4.45M in senior secured convertible notes (9‑month maturity, 22% OID, 8% interest) plus warrants (125% coverage, 5‑year term). Bridge investors have security interest in Acquiror assets (excluding Operating Sub Assets).
• ELOC: up to $50M over three years; Acquiror to issue $1M in commitment shares and a $10M commitment warrant on registration effectiveness; exchange limits (generally 19.99% cap) and stockholder approvals required.
• Operating/Subsidiary support: $7.0M in scheduled deposits to Operating Sub to fund the operating business (various triggers including PIPE closings, Nasdaq milestones); Acquiror believes it has > $2.5M stockholders’ equity for Nasdaq continued listing.

Why It Matters
This filing signals a change in control and capital structure that materially affects shareholders: Lokahi’s former owners will control most of the combined company on a fully‑diluted basis, and significant new financing arrangements can dilute current shareholders further once conversions and equity draws occur. Key post‑closing steps remain: Glucotrack must obtain stockholder approvals (including Nasdaq rules approvals), secure Nasdaq listing/continued‑listing confirmation, complete registration filings, and close a planned PIPE/private placement (up to $30M with a $10M initial closing target). Failure or delays in proxy filings, registration statements, or Nasdaq approvals can affect the timing of preferred conversion, trigger share true‑ups, and may require Glucotrack to issue additional shares or pay liquidated damages under financing agreements. Investors should note the CEO change, the security interest granted to bridge investors (excluding Operating Sub assets), and the scheduling of cash contributions to the operating subsidiary — all items that can influence liquidity, governance, and near‑term equity dilution.